Articles related to CONTRACEPTION/BIRTH CONTROL

This innovative intrauterine device may allow for improvements in discontinuation rates due to pain and bleeding and in expulsion rates.

A comprehensive analysis of 176,601 cancer cases demonstrates that long-acting reversible contraceptives offer a cancer risk profile comparable to oral contraceptives, with data showing a 20-30% reduction in gynecologic cancer risk and a modest increase in breast cancer risk that returns to baseline after cessation.

The court held that damages can extend to the long-term care of the child with special needs.

Long-acting reversible contraceptives show varying effects on cancer risk, with some methods demonstrating protective effects against certain cancers while increasing risks for others.

A national case-control study of 108,366 women found that prolonged use of injectable medroxyprogesterone acetate was associated with a 5.55-fold increased risk of intracranial meningioma requiring surgery (95% CI 2.27-13.56), while levonorgestrel IUDs showed no increased risk.

Vasectomy failure through delayed recanalization presents a rare but documented risk that necessitates thorough patient counseling and robust follow-up protocols.